Bulgari and Dubai Culture announce winner of first Bulgari Contemporary Art Award
23.5.2022 10:38:00 EEST | Business Wire | Press release
In the presence of Her Highness Sheikha Latifa bint Mohammed bin Rashid Al Maktoum, Chairperson of Dubai Culture and Arts Authority (Dubai Culture) and Member of the Dubai Council, Bulgari, the leading Italian brand in the world of jewellery and luxury, and in partnership with Dubai Culture, announced the winner of the first edition of the Bulgari Contemporary Art Award during a ceremony held at the Italy Pavilion at Expo 2020 Dubai. The winner was chosen from a shortlist of three art pieces selected by the award’s jury.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220523005313/en/
Nima Nabavi, winner of the Bulgari Contemporary Art Award, with the trophy (Photo: AETOSWire)
The ceremony was attended by His Excellency Giuseppe Finocchiaro, Consul-General, Italian Consulate (Dubai); Paolo Glisenti, Italy’s Commissioner General for Expo 2020 Dubai; Jean Christophe Babin, Group CEO of Bulgari; Lucia Boscaini, Brand Curator at Bulgari; Her Excellency Hala Badri, Director General of Dubai Culture; and Dr Saeed Mubarak bin Kharbash, CEO of the Arts and Literature Sector at Dubai Culture.
A panel of three experts — Giuseppe Moscatello, Nujoom Alghanem and Patricia Millns FRSA — visited the exhibition held from 3 to 8 February at the Van de Goudenberg Art Gallery in the Dubai International Financial Centre to celebrate the participating works. Among the 15 artworks, the committee shortlisted three artists: Juma AlHaj (UAE), Dubai-based Kamal Alzubi (Jordan), and Dubai-based artist Nima Nabavi (Iranian-American), who the jury selected for the winning artwork.
Nima Nabavi received a trophy that celebrates the aesthetic and cultural dialogue between Rome and Dubai by combining a silhouette inspired by Bulgari’s iconic doorways and storefronts with architectural ornaments inspired from Dubai’s Al Fahidi and Al Shindagha Historical Neighbourhoods. The trophy was designed by Emirati designer Kamla AlOlama and produced by Asateer, an Emirati studio founded by Mohammed AlSuwaidi specialising in contemporary products that reflect the rich Emirati heritage.
The trophy uses materials with great cultural significance. A frame is fabricated from the rich woods of the UAE’s national tree, Al Ghaf, an emblem of heritage and perseverance. The design also incorporates native mother-of-pearl inlaid motifs and brass.
Nima Nabavi expressed his happiness at winning the award and thanked Bulgari and Dubai Culture for giving him the opportunity to share his artistic vision. He also extended his gratitude to the experts and jury for selecting his work for the award.
The winning artwork was exhibited at the Italy Pavilion in Expo 2020. The artist was also offered the opportunity to experience Rome through the eyes of Bulgari as part of a week-long journey through the brand’s universe. He will experience the beauty of Bulgari’s colourful gems and visit the DomvsAvrea museum space in the Maison’s flagship store in Rome, as well as attend workshops with Bulgari designers and exclusive tours of historical sites and cultural locations particularly linked with Bulgari’s patronage, initiatives and inspiration. In addition, the winning piece will be exhibited at venues associated with Dubai Culture and Bulgari, according to a pre-defined schedule.
Launched in July 2021, the Bulgari Contemporary Art Award opened the door for UAE national and resident artists to submit artworks under the theme ‘Beauty Connects People’ that had them creatively express how beauty connects people and how cities like Dubai and Rome are linked by their inspirational beauty and innovation.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220523005313/en/
Contact information
Antoine Boghos, +971503310001
Email address: antoine@cbpr.me
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom